[8] Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study, [9] cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment
Your journey at our Milwaukee clinic begins with a medical consultation where, if you are deemed a suitable candidate, our provider will write a prescription for your customized medication
Hofbauer LC, Witvrouw R, Varga Z, Shiota N, Cremer M, Tanko LB, et al
Here is what the clinical trial data actually shows for both medication classes
Notably, the impact on proliferation was negligible when HG-991-01 was administered at a concentration of 3 M (Goode et al